Clinical

Matching-adjusted indirect comparison methodology was utilized to compare ibrutinib arms across the ALPINE and ELEVATE-RR trials.

New research has shown a link between children’s consumption of ultraprocessed foods and their risk of obesity and other cardiometabolic problems.

A recent study found that screening for hepatocellular carcinoma (HCC) is associated with reduced mortality, highlighting the need to promote HCC screening for patients with known risk factors.

Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center, discusses ways to overcome barriers in clinical trials for diverse patients with psoriasis.

The researchers identified age, tumor metastasis, and surgical treatment as key independent prognostic factors for cardiovascular mortality in patients with ovarian cancer, highlighting the need for individualized treatment and surveillance strategies.

Patients with colorectal cancer (CRC) had lower 5-year survival if they had type 2 diabetes.

The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.

The FDA has approved tarlatamab (Imdelltra; Amgen), a novel bispecific T-cell engager, to treat patients with extensive-stage small cell lung cancer (SCLC).

This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).

A very unusual case of lip-based diffuse large B-cell lymphoma (DLBCL) was treated successfully thanks to prompt diagnosis and chemotherapy treatments.

Underlying mood and sleep disorders may negatively affect asthma control, researchers find.

Italian patients with chronic obstructive pulmonary disease (COPD) face a significantly increased risk of severe cardiovascular events.

Patients with HIV who switched to a treatment regimen that included tenofovir alafenamide (TAF) showed improvement in serum markers for hepatic steatosis (HS) among other benefits.

Other findings from the latest Kaiser Family Foundation Health Tracking Poll shed light on public awareness, use, and opinions on Medicare coverage of glucagon-like peptide-1 (GLP-1) drugs.

Researchers compare treatments and outcomes in patients with Sydenham chorea, finding faster resolution with corticosteroid treatment.

FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory (R/R) follicular lymphoma.

Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.

Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.

Due to the rarity of primary breast lymphoma, individualized treatment plans that consider overall health, symptoms, and patient preferences should be curated.

Robot-assisted laparoscopic surgery was found to be more effective in harvesting lymph nodes compared with conventional surgery with similar outcomes.

Due to increasing reports of multiple myeloma and the emergence of chimeric antigen receptor (CAR) T-cell therapy as a treatment option, these investigators conducted a comprehensive review of the medical literature on the latest CAR T developments in the MM space.

Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).

Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, shares what women can do to prioritize their heart health during National Women's Health Week and every week.

Panelists delve into the data and the cost-saving evidence required by payers to cover prescription digital therapeutics (PDTs), outline the decision-making process followed by payers, and share best practices observed in real-world to ensure the successful implementation of PDTs.

Diana Brixner, PhD, and Ashley Peterson, MHA, explore the distinctions between prescription digital therapeutics (PDTs) and wellness mobile apps, addressing the role of insurance coverage and the clinical validation requirements that payers consider when determining whether to cover PDTs as a treatment modality.